Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2015 1
2016 1
2019 1
2020 2
2021 4
2022 5
2023 6
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

19 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for olanzapine mylan
Your search for olanzapina-mylan retrieved no results
Olanzapine.
[No authors listed] [No authors listed] 2022 Nov 30. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. 2022 Nov 30. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. PMID: 30000115 Free Books & Documents. Review.
Maternal doses of olanzapine up to 20 mg daily produce low levels in milk and undetectable levels in the serum of breastfed infants. In most cases, short-term side effects have not been reported, but sedation has occurred. Limited long-term follow-up of infants exposed to …
Maternal doses of olanzapine up to 20 mg daily produce low levels in milk and undetectable levels in the serum of breastfed infants. …
Effect of the GLP-1 receptor agonist semaglutide on metabolic disturbances in clozapine-treated or olanzapine-treated patients with a schizophrenia spectrum disorder: study protocol of a placebo-controlled, randomised clinical trial (SemaPsychiatry).
Sass MR, Danielsen AA, Köhler-Forsberg O, Storgaard H, Knop FK, Nielsen MØ, Sjödin AM, Mors O, Correll CU, Ekstrøm C, Vinberg M, Nielsen J, Vilsbøll T, Fink-Jensen A. Sass MR, et al. BMJ Open. 2023 Jan 31;13(1):e068652. doi: 10.1136/bmjopen-2022-068652. BMJ Open. 2023. PMID: 36720576 Free PMC article.
INTRODUCTION: Clozapine and olanzapine are some of the most effective antipsychotics, but both are associated with weight gain and relevant metabolic disturbances, including pre-diabetes and diabetes. ...We will investigate the long-term effects of add-on treatment with se …
INTRODUCTION: Clozapine and olanzapine are some of the most effective antipsychotics, but both are associated with weight gain and re …
The impact of pharmacological and non-pharmacological interventions on physical health outcomes in people with mood disorders across the lifespan: An umbrella review of the evidence from randomised controlled trials.
Croatto G, Vancampfort D, Miola A, Olivola M, Fiedorowicz JG, Firth J, Alexinschi O, Gaina MA, Makkai V, Soares FC, Cavaliere L, Vianello G, Stubbs B, Fusar-Poli P, Carvalho AF, Vieta E, Cortese S, Shin JI, Correll CU, Solmi M. Croatto G, et al. Mol Psychiatry. 2023 Jan;28(1):369-390. doi: 10.1038/s41380-022-01770-w. Epub 2022 Sep 22. Mol Psychiatry. 2023. PMID: 36138129 Free PMC article.
Among youths, against placebo, in depression, antidepressants/antipsychotics had higher discontinuation rates; in bipolar depression, olanzapine+fluoxetine worsened total cholesterol (TC)/triglycerides/weight gain (WG) (large ES). In adults with bipolar disorder, olanza …
Among youths, against placebo, in depression, antidepressants/antipsychotics had higher discontinuation rates; in bipolar depression, ola …
Amisulpride and olanzapine combination treatment versus each monotherapy in acutely ill patients with schizophrenia in Germany (COMBINE): a double-blind randomised controlled trial.
Schmidt-Kraepelin C, Feyerabend S, Engelke C, Riesbeck M, Meisenzahl-Lechner E, Verde PE, Correll CU, Kluge M, Makiol C, Neff A, Lange C, Englisch S, Zink M, Langguth B, Poeppl TB, Reske D, Gouzoulis-Mayfrank E, Gründer G, Hasan A, Brockhaus-Dumke A, Jäger M, Baumgärtner J, Leucht S, Cordes J; COMBINE Study Group. Schmidt-Kraepelin C, et al. Lancet Psychiatry. 2022 Apr;9(4):291-306. doi: 10.1016/S2215-0366(22)00032-3. Epub 2022 Mar 8. Lancet Psychiatry. 2022. PMID: 35276079 Clinical Trial.
To keep patients and investigators masked throughout the duration of the trial, amisulpride, olanzapine, and placebo were administered as identical capsules. Flexibly dosed monotherapy of oral amisulpride (amisulpride plus placebo, 200-800 mg per day) or olanzapine …
To keep patients and investigators masked throughout the duration of the trial, amisulpride, olanzapine, and placebo were administere …
Efficacy and safety of antiemetic regimens for highly emetogenic chemotherapy-induced nausea and vomiting: A systematic review and network meta-analysis.
Filetti M, Lombardi P, Giusti R, Falcone R, Scotte F, Giannarelli D, Carcagnì A, Altamura V, Scambia G, Daniele G. Filetti M, et al. Cancer Treat Rev. 2023 Apr;115:102512. doi: 10.1016/j.ctrv.2023.102512. Epub 2023 Jan 21. Cancer Treat Rev. 2023. PMID: 36774658 Free article.
CONCLUSION: In our network meta-analysis, 4-drug regimens with olanzapine displayed the highest probability of efficacy in terms of complete response. A 3-drug regimen with olanzapine represents a valid option in a limited resource context....
CONCLUSION: In our network meta-analysis, 4-drug regimens with olanzapine displayed the highest probability of efficacy in terms of c …
Asenapine versus olanzapine for the treatment of nausea and vomiting in patients with cancer: A retrospective study.
Kimura T, Kanai A, Muraoka H, Takahashi Y, Ara M, Inada K. Kimura T, et al. Neuropsychopharmacol Rep. 2024 Mar;44(1):158-164. doi: 10.1002/npr2.12412. Epub 2024 Jan 19. Neuropsychopharmacol Rep. 2024. PMID: 38239112 Free PMC article.
AIM: Patients with cancer often experience nausea and vomiting (N/V), but may have difficulty using olanzapine (OLZ), a common antiemetic. Asenapine (ASE) is a multi-acting receptor-targeted antipsychotic like OLZ, although there is little evidence that ASE serves as an an …
AIM: Patients with cancer often experience nausea and vomiting (N/V), but may have difficulty using olanzapine (OLZ), a common antiem …
Olanzapine Plus Samidorphan in Subjects with Schizophrenia and Comorbid Alcohol Use Disorder: Rationale and Design for a Phase II, Double-blind, Randomized Study.
Citrome L, O'Malley SS, McDonnell D, Jiang Y, Simmons AC, Berry MP, Dipetrillo LE. Citrome L, et al. Innov Clin Neurosci. 2019 May 1;16(5-6):15-21. Innov Clin Neurosci. 2019. PMID: 31440397 Free PMC article.
Methods: We describe the design of a Phase II, double-blind, randomized trial to evaluate adult outpatients with schizophrenia and comorbid AUD receiving a combination of olanzapine plus samidorphan (OLZ+SAM; ALKS 3831), a novel entity currently under development for the t …
Methods: We describe the design of a Phase II, double-blind, randomized trial to evaluate adult outpatients with schizophrenia and comorbid …
Mortality risk of antipsychotic augmentation for adult depression.
Gerhard T, Stroup TS, Correll CU, Setoguchi S, Strom BL, Huang C, Tan Z, Crystal S, Olfson M. Gerhard T, et al. PLoS One. 2020 Sep 30;15(9):e0239206. doi: 10.1371/journal.pone.0239206. eCollection 2020. PLoS One. 2020. PMID: 32997687 Free PMC article.
RESULTS: The analytic cohort included 39,582 patients (female = 78.5%, mean age = 44.5 years) who initiated augmentation with a newer antipsychotic (n = 22,410; 40% = quetiapine, 21% = risperidone, 17% = aripiprazole, 16% = olanzapine) or with a second antidepressant (n = …
RESULTS: The analytic cohort included 39,582 patients (female = 78.5%, mean age = 44.5 years) who initiated augmentation with a newer antips …
19 results